Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KDM4E | B2RXH2 | 4/20 | 1.00 |
| ▸ | HTR3E | A5X5Y0 | 4/20 | 1.00 |
| ▸ | HTR3B | O95264 | 4/20 | 1.00 |
| ▸ | HTR3A | P46098 | 4/20 | 1.00 |
| ▸ | HTR3D | Q70Z44 | 4/20 | 1.00 |
| ▸ | HTR3C | Q8WXA8 | 4/20 | 1.00 |
| ▸ | ALDH1A1 | P00352 | 4/20 | 1.00 |
| ▸ | CYP3A4 | P08684 | 3/20 | 1.00 |
| ▸ | CYP1A2 | P05177 | 3/20 | 1.00 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 1.00 |
| ▸ | ADRB1 | P08588 | 2/20 | 1.00 |
| ▸ | TDP1 | Q9NUW8 | 2/20 | 1.00 |
| ▸ | SLC6A4 | P31645 | 2/20 | 1.00 |
| ▸ | USP2 | O75604 | 1/20 | 1.00 |
| ▸ | HTR1A | P08908 | 1/20 | 1.00 |
| ▸ | HTR2C | P28335 | 1/20 | 1.00 |
| ▸ | MAPK1 | P28482 | 1/20 | 1.00 |
| ▸ | HTR7 | P34969 | 1/20 | 1.00 |
| ▸ | HTT | P42858 | 1/20 | 1.00 |
| ▸ | HTR6 | P50406 | 1/20 | 1.00 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Quipazine SCHEMBL4062074 | 0.98 | KDM4E (0.97) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL3227424 | 0.94 | KDM4E (0.88) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL6918242 | 0.90 | KDM4E (0.81) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| Quipazine SCHEMBL124520 | 0.87 | KDM4E (1.00) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| Quipazine SCHEMBL29868311 | 0.87 | KDM4E (1.00) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| Quipazine SCHEMBL10529419 | 0.87 | KDM4E (1.00) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL30824499 | 0.83 | HRH3 (0.71) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL5664122 | 0.83 | HRH3 (0.71) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL29604668 | 0.83 | HRH3 (0.71) | KDM4EHTR3EHTR3BHTR3AHTR3D | |
| SCHEMBL844364 | 0.81 | HRH3 (0.69) | KDM4EHTR3EHTR3BHTR3AHTR3D |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1284 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-4358962-B1 | TREATMENT FOR AUTOIMMUNE DISEASES COMPRISING NALTREXONE OR A METABOLITE OR ANALOG THEREOF, A CANNABINOID AND A 5-HT RECEPTOR AGONIST | LDN PHARMA LTD (GB) | 2026-02-04 | — | — | EP | claimed |
| US-12434068-B2 | Accessing spinal networks to address sexual dysfunction | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2025-10-07 | — | — | US | claimed |
| EP-4299106-B1 | ACCESSING SPINAL NETWORK TO ENABLE RESPIRATORY FUNCTION | UNIV CALIFORNIA (US) | 2025-09-03 | — | — | EP | claimed |
| US-20240374541-A1 | ENGAGING THE CERVICAL SPINAL CORD CIRCUITRY TO RE-ENABLE VOLITIONAL CONTROL OF HAND FUNCTION IN TETRAPLEGIC SUBJECTS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-11-14 | — | — | US | claimed |
| EP-4442332-A2 | REGULATION OF AUTONOMIC CONTROL OF BLADDER VOIDING AFTER A COMPLETE SPINAL CORD INJURY | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2024-10-09 | — | — | EP | claimed |
| US-20240252535-A1 | CELLULAR COMPOSITION FOR TREATMENT OF DISEASES, DISORDERS OR CONDITIONS AND METHOD OF USE | YZTHERAPEUTIC PERFORMANCE LTD. (IL) | 2024-08-01 | — | — | US | claimed |
| EP-4358962-A1 | TREATMENT FOR AUTOIMMUNE DISEASES | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| EP-4358943-A1 | NALTREXONE FOR BOOSTING THE THERAPEUTIC UTILITY OF 5-HT RECEPTOR AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| EP-4358960-A1 | COMPOSITIONS COMPRISING AN AGONIST OF 5-HYDROXYTRYPTAMINE (5-HT) RECEPTOR SUBTYPE 3 | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| EP-4358961-A1 | NALTREXONE FOR IMPROVING THE EFFECTIVENESS OF 5-HT RECEPTOR SUBTYPE 2A, 2B OR 2C AGONISTS | LDN Pharma Limited (GB) | 2024-05-01 | — | — | EP | claimed |
| EP-0494256-A4 | EVALUATIVE MEANS FOR DETECTING INFLAMMATORY REACTIVITY AND FOR PREDICTING RESPONSE TO STRESS | US HEALTH (US) | 1992-08-12 | — | — | EP | claimed |
| EP-0494256-A1 | EVALUATIVE MEANS FOR DETECTING INFLAMMATORY REACTIVITY AND FOR PREDICTING RESPONSE TO STRESS | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1992-07-15 | — | — | EP | claimed |
| EP-0446282-A1 | EVALUATIVE MEANS FOR DETECTING INFLAMMATORY REACTIVITY | THE UNITED STATES OF AMERICA as represented by the Secretary UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-09-18 | — | — | EP | claimed |
| EP-0440704-A1 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWEL SYMPTOMS. | MASSACHUSETTS INST TECHNOLOGY (US) | 1991-08-14 | — | — | EP | claimed |
| WO-1991004479-A1 | EVALUATIVE MEANS FOR DETECTING INFLAMMATORY REACTIVITY AND FOR PREDICTING RESPONSE TO STRESS | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1991-04-04 | — | — | WO | claimed |
| EP-0386117-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-09-12 | — | — | EP | claimed |
| WO-1990006112-A1 | EVALUATIVE MEANS FOR DETECTING INFLAMMATORY REACTIVITY | THE UNITED STATES OF AMERICA, REPRESENTED BY THE SECRETARY, UNITED STATES DEPARTMENT OF COMMERCE (US) | 1990-06-14 | — | — | WO | claimed |
| WO-1990004387-A2 | COMPOSITIONS FOR TREATING TOBACCO WITHDRAWAL SYMPTOMS | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1990-05-03 | — | — | WO | claimed |
| WO-1989003692-A1 | TREATING PREMENSTRUAL OR LATE LUTEAL PHASE SYNDROME | MASSACHUSETTS INSTITUTE OF TECHNOLOGY (US) | 1989-05-05 | — | — | WO | claimed |
| US-4742054-A | Treatment of mammals suffering from damage to the central nervous system | NAFTCHI NOSRAT E (US) | 1988-05-03 | — | — | US | claimed |